| 02/07 | Ascendis Pharma Announces Full Year 2022 Financial Results and Business Update Conferen.. | AQ |
| 01/18 | Tech Stocks Lead European Equities Modestly Higher in Wednesday Trading | MT |
| 01/17 | Pharma Stocks Lead European Equities Higher in Tuesday Trading | MT |
| 01/17 | SVB Securities Adjusts Price Target on Ascendis Pharma to $163 From $148, Maintains Out.. | MT |
| 01/10 | BioAtla Sees Dosing of First Patient in Mid-Stage Part 2 Study in Soft Tissue Cancer Th.. | MT |
| 01/09 | Transcript : Ascendis Pharma A/S Presents at 41st Annual J.P. Morgan Healthca.. | CI |
| 01/09 | European Equities Begin Week With Sharp Rise | MT |
| 01/09 | Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K | PU |
| 01/08 | Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Mor.. | AQ |
| 01/04 | Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma.. | AQ |
| 01/03 | Ascendis Pharma A/s : Articles of Association - Form 6-K | PU |
| 01/03 | Wells Fargo Boosts Price Target on Ascendis Pharma to $177 From $169, Keeps Overweight .. | MT |
| 01/03 | Ascendis Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference | AQ |
| 2022 | Ascendis Pharma A/s : Articles of Association - Form 6-K | PU |
| 2022 | After Seesaw Opening, European Equities Little Changed in Monday Trading | MT |
| 2022 | Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K | PU |
| 2022 | Ascendis Pharma A/S Announces U.S. Food & Drug Administration Allows to Initiate an Exp.. | CI |
| 2022 | Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult .. | AQ |
| 2022 | European Equities Nudge Higher on Slightly Lower Euro Area Inflation | MT |
| 2022 | Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference | AQ |
| 2022 | European Equities Flat in Choppy Trade Wednesday as Geopolitical Tensions Weigh | MT |
| 2022 | Morgan Stanley Adjusts Price Target on Ascendis Pharma to $148 From $146, Maintains Ove.. | MT |
| 2022 | Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines A.. | AQ |
| 2022 | European ADRs Continue to Trend Higher in Monday Trading | MT |
| 2022 | Ascendis Pharma Submits Marketing Authorization Application in EU for Hypoparathyroidis.. | MT |
| 2022 | Dose Escalation Data from transcendIT-101 Ascendis Pharma's Phase 1/2 Trial of TransCon.. | AQ |
| 2022 | Once-Weekly TransCon CNP Achieved Primary Efficacy Objective, with Superiority at 100 -.. | AQ |
| 2022 | Transcript : Ascendis Pharma A/S - Special Call | CI |
| 2022 | Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K | PU |
| 2022 | Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines A.. | AQ |
| 2022 | Ascendis Pharma Submits Marketing Authorization Application to the European Medicines A.. | CI |
| 2022 | Wedbush Raises Price Target on Ascendis Pharma to $164 From $151, Keeps Outperform Rati.. | MT |
| 2022 | Ascendis Pharma A/s : TransCon™ CNP ACcomplisH Trial Topline Results | PU |
| 2022 | Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority a.. | AQ |
| 2022 | TransCon CNP Achieves Primary Efficacy Objective, with Superiority at 100 µg/kg/week, i.. | CI |
| 2022 | ADRs End Higher; Ascendis Pharma, ASML Holding Trade Actively | DJ |
| 2022 | Ascendis Pharma A/s : TransCon™ TLR7/8 Agonist Initial Results from Dose Escalation .. | PU |
| 2022 | Dose Escalation Data from transcendIT-101, Ascendis Pharma's Phase 1/2 Trial of TransCo.. | AQ |
| 2022 | Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of Tr.. | CI |
| 2022 | Ascendis Pharma A/s : Articles of Association - Form 6-K | PU |
| 2022 | Wells Fargo Adjusts Price Target on Ascendis Pharma to $169 From $172, Maintains Overwe.. | MT |
| 2022 | European Bourses Close Mostly Lower as EU Unemployment Rate Declines | MT |
| 2022 | Citigroup Adjusts Price Target on Ascendis Pharma A/S to $163 From $157, Maintains Buy .. | MT |
| 2022 | European ADRs Regain Some Early Losses on Thursday | MT |
| 2022 | Credit Suisse Adjusts Ascendis Pharma's Price Target to $130 From $123, Keeps Outperfor.. | MT |
| 2022 | Morgan Stanley Adjusts Price Target on Ascendis Pharma A/S to $146 From $148, Maintains.. | MT |
| 2022 | Oppenheimer Adjusts Ascendis Pharma Price Target to $150 From $144, Maintains Outperfor.. | MT |
| 2022 | Wedbush Raises Ascendis Pharma's Price Target to $151 From $144 After Q3 SKYTROFA Sales.. | MT |
| 2022 | Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K | PU |
| 2022 | Transcript : Ascendis Pharma A/S, Q3 2022 Earnings Call, Nov 02, 2022 | CI |
| 2022 | Earnings Flash (ASND) ASCENDIS PHARMA Reports Q3 Revenue EUR15.3M | MT |
| 2022 | Ascendis Pharma Reports Third Quarter 2022 Financial Results | AQ |
| 2022 | Ascendis Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ende.. | CI |
| 2022 | FDA Accepts for Priority Review Ascendis Pharma's NDA for TransCon PTH in Adult Patient.. | AQ |
| 2022 | Ascendis Pharma Says FDA Grants Priority Review to Hypoparathyroidism Treatment TransCo.. | MT |
| 2022 | Ascendis Pharma Gets FDA Acceptance for Priority Review of TransCon PTH | DJ |
| 2022 | Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K | PU |
| 2022 | FDA Accepts for Priority Review Ascendis Pharma's NDA for TransCon™ PTH in Adult .. | AQ |
| 2022 | Ascendis Pharma A/S Announces FDA Accepts for Priority Review Its NDA for TransCon(TM) .. | CI |
| 2022 | Ascendis Pharma A/S Announces Third Quarter 2022 Financial Results and Business Update .. | AQ |
| 2022 | Goldman Sachs Initiates Coverage on Ascendis Pharma With Buy Rating, $174 Price Target | MT |
| 2022 | European ADRs Move Higher in Thursday Trading | MT |
| 2022 | Ascendis Pharma A/s : Articles of Association - Form 6-K | PU |
| 2022 | European ADRs Move Slightly Lower in Wednesday Trading | MT |
| 2022 | European ADRs Move Sharply Lower in Wednesday Trading | MT |
| 2022 | Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K | PU |
| 2022 | European ADRs Surge Higher in Monday Trading | MT |
| 2022 | Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT.. | AQ |
| 2022 | Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for TranscendIT.. | CI |
| 2022 | Ascendis Pharma A/s : Articles of Association - Form 6-K | PU |
| 2022 | Ascendis Pharma Added to Wedbush Best Ideas List | MT |
| 2022 | European ADRs Move Lower in Thursday Trading | MT |
| 2022 | Wells Fargo Adjusts Ascendis Pharma Price Target to $172 From $167, Maintains Overweigh.. | MT |
| 2022 | Ascendis Pharma A/s : Articles of Association - Form 6-K | PU |
| 2022 | Transcript : Ascendis Pharma A/S Presents at Morgan Stanley 20th Annual Globa.. | CI |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
